Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 85

Related Articles by Review for PubMed (Select 18706957)

1.

The cost-effectiveness of using hepatitis A/B combined vaccine versus hepatitis B vaccine alone for high-risk heterosexuals.

Rein DB, Weinbaum CM.

Vaccine. 2008 Oct 3;26(42):5331-3. doi: 10.1016/j.vaccine.2008.07.089. Epub 2008 Aug 14.

PMID:
18706957
2.

Cost-effectiveness analyses of hepatitis A vaccine: a systematic review to explore the effect of methodological quality on the economic attractiveness of vaccination strategies.

Anonychuk AM, Tricco AC, Bauch CT, Pham B, Gilca V, Duval B, John-Baptiste A, Woo G, Krahn M.

Pharmacoeconomics. 2008;26(1):17-32. Review.

PMID:
18088156
3.

The A's and B's of vaccine-preventable hepatitis: improving prevention in high-risk adults.

Oldfield EC 3rd, Keeffe EB.

Rev Gastroenterol Disord. 2007 Winter;7(1):1-21. Review.

PMID:
17392626
4.

Hepatitis B immunization in adolescents.

Lawrence MH, Goldstein MA.

J Adolesc Health. 1995 Oct;17(4):234-43. Review.

PMID:
8580124
5.

Cost-effectiveness of hepatitis A vaccination in children, adolescents, and adults.

Rosenthal P.

Hepatology. 2003 Jan;37(1):44-51. Review.

PMID:
12500187
6.

Hepatitis A and considerations regarding the cost-effectiveness of vaccination programs.

Deneke MG, Arguedas MR.

Expert Rev Vaccines. 2003 Oct;2(5):661-72. Review.

PMID:
14711327
7.

[Combined vaccine against hepatitis A and B].

Pawłowska M, Halota W, Kozielewicz D.

Przegl Epidemiol. 2004;58 Suppl 1:66-70. Review. Polish.

PMID:
15807160
8.

The underestimated risk of hepatitis A and hepatitis B: benefits of an accelerated vaccination schedule.

Keystone JS, Hershey JH.

Int J Infect Dis. 2008 Jan;12(1):3-11. Epub 2007 Jul 20. Review.

9.
10.
11.

Bivalent inactivated hepatitis A and recombinant hepatitis B vaccine.

Beran J.

Expert Rev Vaccines. 2007 Dec;6(6):891-902. doi: 10.1586/14760584.6.6.891. Review.

PMID:
18377352
13.

Economic evaluations of hepatitis B vaccination for developing countries.

Tu HA, Woerdenbag HJ, Kane S, Riewpaiboon A, van Hulst M, Postma MJ.

Expert Rev Vaccines. 2009 Jul;8(7):907-20. doi: 10.1586/erv.09.53. Review.

PMID:
19538116
14.

Economic evaluation of vaccination programmes: a consensus statement focusing on viral hepatitis.

Beutels P, Edmunds WJ, Antoñanzas F, De Wit GA, Evans D, Feilden R, Fendrick AM, Ginsberg GM, Glick HA, Mast E, Péchevis M, Van Doorslaer EK, van Hout BA; Viral Hepatitis Prevention Board.

Pharmacoeconomics. 2002;20(1):1-7. Review.

PMID:
11817988
15.

[Viral hepatitis: preventable illnesses].

Baumgarten R.

Z Arztl Fortbild Qualitatssich. 1998 Dec;92(10):677-80. Review. German.

PMID:
10028595
16.

Adverse events after hepatitis A B combination vaccine.

Woo EJ, Miller NB, Ball R; VAERS Working Group.

Vaccine. 2006 Mar 24;24(14):2685-91. Epub 2005 Nov 9. Review.

PMID:
16310295
17.

[Vaccination against hepatitis A and B].

Delwaide J, Belaiche J.

Rev Med Liege. 1997 Oct;52(10):639-43. Review. French. No abstract available.

PMID:
9446163
18.

Who should receive hepatitis A vaccine?

Arankalle VA, Chadha MS.

J Viral Hepat. 2003 May;10(3):157-8. Review.

PMID:
12753332
19.

A review of combined hepatitis A and hepatitis B vaccination for travelers.

Spira AM.

Clin Ther. 2003 Sep;25(9):2337-51. Review.

PMID:
14604737
20.

Experience with hepatitis A and B vaccines.

Davis JP.

Am J Med. 2005 Oct;118 Suppl 10A:7S-15S. Review.

PMID:
16271535
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk